Friday – Clinical Track 2A

Full Name(Required)
Enter your first and last names as you would like them to appear on your certificates.
Enter the email you used to register for TOXINS 2022.

Please evaluate the speakers

ExcellentGoodFairPoor
BoNT for Suppression of Chronic Migraine: What Have We Learned in 10+ Years? (Peter McAllister)
Potential Use of BoNT in Treating Other Primary Headache Disorders and Facial Pain (Cristina Tassorelli)
BoNT, mAbs, and Gepants: Elegant Synergism or Expensive Redundancy? (Peter McAllister)
Real-World Safety and Efficacy of 156-195 U OnabotulinumtoxinA in Participants With Chronic Migraine: Results From the REPOSE Study (Katherine Sommer)
Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine (Jennifer W. McVige)
Consecutive Headache-Free Days With OnabotulinumtoxinA Treatment in Patients With Chronic Migraine: A Pooled PREEMPT Analysis (Katherine Sommer)
YesNo
BoNT for Suppression of Chronic Migraine: What Have We Learned in 10+ Years? (Peter McAllister)
Potential Use of BoNT in Treating Other Primary Headache Disorders and Facial Pain (Cristina Tassorelli)
BoNT, mAbs, and Gepants: Elegant Synergism or Expensive Redundancy? (Peter McAllister)
Real-World Safety and Efficacy of 156-195 U OnabotulinumtoxinA in Participants With Chronic Migraine: Results From the REPOSE Study (Katherine Sommer)
Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine (Jennifer W. McVige)
Consecutive Headache-Free Days With OnabotulinumtoxinA Treatment in Patients With Chronic Migraine: A Pooled PREEMPT Analysis (Katherine Sommer)
YesNo
BoNT for Suppression of Chronic Migraine: What Have We Learned in 10+ Years? (Peter McAllister)
Potential Use of BoNT in Treating Other Primary Headache Disorders and Facial Pain (Cristina Tassorelli)
BoNT, mAbs, and Gepants: Elegant Synergism or Expensive Redundancy? (Peter McAllister)
Real-World Safety and Efficacy of 156-195 U OnabotulinumtoxinA in Participants With Chronic Migraine: Results From the REPOSE Study (Katherine Sommer)
Real-world Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients With Chronic Migraine (Jennifer W. McVige)
Consecutive Headache-Free Days With OnabotulinumtoxinA Treatment in Patients With Chronic Migraine: A Pooled PREEMPT Analysis (Katherine Sommer)
Strongly disagreeDisagreeNeutralAgreeStrongly agree
Ability to evaluate the latest clinical and scientific research into botulinum neurotoxins
Understanding of the clinical utility of botulinum neurotoxins
Understanding of potential new therapeutic applications of botulinum neurotoxins
Biomedical knowledge of botulinum and other neurotoxins and their application in enhancing therapeutics and improving care